Literature DB >> 22030290

Use of the loop diuretic torsemide in three dogs with advanced heart failure.

Mark A Oyama1, Gordon D Peddle, Caryn A Reynolds, Gretchen E Singletary.   

Abstract

Diuretics are a mainstay of therapy in dogs with heart failure. In dogs with advanced heart failure, moderate to high doses of loop diuretics such as furosemide are used with diminishing effects as profound activation of neuroendocrine systems promote signs of congestive heart failure. The loop diuretic torsemide has several characteristics that make it suitable for treatment of advanced heart failure including longer half-life, increased potency of diuretic action, and anti-aldosterone effects. This case report details the administration of torsemide in 3 dogs with advanced heart failure and apparent furosemide resistance.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030290     DOI: 10.1016/j.jvc.2011.10.001

Source DB:  PubMed          Journal:  J Vet Cardiol        ISSN: 1760-2734            Impact factor:   1.701


  11 in total

1.  Safety of torasemide in healthy adult dogs administered daily for 26 weeks.

Authors:  Evelyne Coussanes; Emilie Guillot; Reynald Magnier; Anne Geneteau; Jonathan Elliott
Journal:  J Vet Pharmacol Ther       Date:  2021-11-17       Impact factor: 1.567

2.  Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.

Authors:  V Chetboul; J-L Pouchelon; J Menard; J Blanc; L Desquilbet; A Petit; S Rougier; L Lucats; F Woehrle
Journal:  J Vet Intern Med       Date:  2017-10-04       Impact factor: 3.333

3.  Long-term Stability of a Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration.

Authors:  D Adin; P R Johnson; C H Kim; T Nguyenba; S Rosen
Journal:  J Vet Intern Med       Date:  2017-09-15       Impact factor: 3.333

4.  ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.

Authors:  Bruce W Keene; Clarke E Atkins; John D Bonagura; Philip R Fox; Jens Häggström; Virginia Luis Fuentes; Mark A Oyama; John E Rush; Rebecca Stepien; Masami Uechi
Journal:  J Vet Intern Med       Date:  2019-04-11       Impact factor: 3.333

5.  Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.

Authors:  Darcy Adin; Kari Kurtz; Clarke Atkins; Mark G Papich; Shelly Vaden
Journal:  J Vet Intern Med       Date:  2019-11-26       Impact factor: 3.333

6.  The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.

Authors:  Basile Gravez; Antoine Tarjus; Ruben Jimenez-Canino; Soumaya El Moghrabi; Smail Messaoudi; Diego Alvarez de la Rosa; Frederic Jaisser
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 7.  Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease.

Authors:  Giulio Menciotti; Michele Borgarelli
Journal:  Vet Sci       Date:  2017-09-26

8.  Tolerance of torasemide in cats with congestive heart failure: a retrospective study on 21 cases (2016-2019).

Authors:  Camille Poissonnier; Sarra Ghazal; Peggy Passavin; Maria-Paz Alvarado; Solène Lefort; Emilie Trehiou-Sechi; Vittorio Saponaro; Alix Barbarino; Julia Delle Cave; Charlie-Rose Marchal; Boris Depré; Etienne Vannucci; Renaud Tissier; Patrick Verwaerde; Valérie Chetboul
Journal:  BMC Vet Res       Date:  2020-09-16       Impact factor: 2.741

9.  Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study.

Authors:  Beatrice Besche; Thomas Blondel; Emilie Guillot; Catherine Garelli-Paar; Mark A Oyama
Journal:  J Vet Intern Med       Date:  2020-08-07       Impact factor: 3.333

Review 10.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.